The FDA has approved Keytruda (pembrolizumab; Merck), a programmed death receptor-1 -blocking antibody, as monotherapy for the first-line treatment of patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer.
Other factors associated with risk include anemia, cardiac arrhythmia, hypertension, smoking history, obesity
Researchers assessed whether adherence to oral antidiabetic medication was a modifiable prognostic factor in patients with CRC and preexisting diabetes.
This study focused on a cohort of nonelderly Medicaid beneficiaries with stage IV breast or colorectal cancer who resided in New Jersey.
Almost all who met criteria for early screening could have initiated screening before age of diagnosis.